Short answer
Boston Scientific (BSX) filed its Q3 2026 10-Q quarterly report on Nov 2, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $5.1B (up 1.5% year over year) with net income of $583M.
Q3 2026 key financials · XBRL
- Revenue
- $5.1B
- +1.5% YoY · −5.6% QoQ
- Net income
- $583M
- −22.8% YoY · −35.7% QoQ
- Operating margin
- 16.1%
- Gross margin
- 66.7%
- EPS (diluted)
- $0.41
- −19.6% YoY · −32.8% QoQ
Source: XBRL data from the Boston Scientific (BSX) Q3 2026 10-Q on SEC EDGAR. USD.
Boston Scientific Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $5.138B, up 1.5% YoY from $5.065B
- Gross margin 66.7% vs 69.9% YoY; adjusted net income $1.063B vs $1.124B
- Best segment Cardiovascular, $3.406B, up 1.9%; worst Urology, down 3.2%
- Operating cash flow $2.870B for nine months vs $3.170B; $2.000B share repurchase
- Headwinds: cybersecurity disruption, Electrophysiology competition, WATCHMAN™ market deceleration, tariff uncertainty
Risk Factors
- Cybersecurity incident risk: August 26, 2026 incident could disrupt operations and financial results
- Penumbra acquisition regulatory risk: FTC issued a Second Request on March 16, 2026
- Spinal cord stimulator litigation risk: MDL consolidated federal product-liability cases on June 5, 2026
- Supply-chain restructuring risk: 2026 plan transfers production lines through 2029
- Commercial paper liquidity risk: $1.029 billion outstanding, reducing available capacity to $1.721 billion
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Boston Scientific quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.